Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management
- 4 August 2019
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 44 (7), 740-746
- https://doi.org/10.1111/ced.14041
Abstract
Pemphigus diseases are cutaneous and mucous membrane blistering diseases, related to the key antigens of desmoglein 1 and 3. This article reviews the topic, including diagnosis, and provides the physician with guidance on the treatment of these difficult to control disorders.Keywords
This publication has 8 references indexed in Scilit:
- The optimal oral biopsy site for diagnosis of mucous membrane pemphigoid and pemphigus vulgarisBritish Journal of Dermatology, 2019
- An Oral Disease Severity Score validated for use in oral pemphigus vulgarisBritish Journal of Dermatology, 2018
- British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017British Journal of Dermatology, 2017
- First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialThe Lancet, 2017
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008
- The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levelsBritish Journal of Dermatology, 2001
- Diagnostic Patterns and Delays in Pemphigus Vulgaris: Experience With 99 PatientsArchives of Dermatology, 2000
- The Adjuvant Therapy of PemphigusArchives of Dermatology, 1996